Mendelspod Podcast

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.

https://mendelspod.com/

Eine durchschnittliche Folge dieses Podcasts dauert 29m. Bisher sind 435 Folge(n) erschienen. Alle 5 Tage erscheint eine Folge dieses Podcasts
subscribe
share



 

Anya Prince on Our Current Vulnerability to Genetic Discrimination


Some Americans still resist genetic testing for fear they will be discriminated against by insurance companies. Why? in 2008, Congress passed GINA, the Genetic Information Nondiscrimination Act, to protect us from insurance companies choosing to include us or not for policies based on the genes we came with. Then in 2010, Congress passed the ACA, or Affordable Care Act, and with it protection against preexisting conditions. This includes genetic predispositions.


share





   n/a
 
 

Do Long Reads Hold Answers for Alzheimer’s? with Mark Ebbert, Mayo


It’s the kind of plot that makes great science. There are genes that have been hiding in plain sight, undetected until now. They’ve gone unseen, that is, by short read sequencing. Today’s guest and his colleagues call them “camouflage genes,” and a couple in particular may play functional roles in Alzheimer’s disease...


share





   n/a
 
 

With Nanopore Sensing Beyond Sequencing, Ontera Takes 'Lab' to the Field


We’ve interviewed several CEOs over the years since the Theranos fiasco who avoided any mention of the blighted company whenever the comparison came up. But today’s guest, Murielle Thinard McLane, the CEO of Ontera, jumped at the chance before Theral could get to it. "Some people might say, well that's the Theranos model. They (Theranos) didn't get it wrong. The demand for a fast, comprehensive point-of-care solution near the patient is there...


share





   n/a
 
 

With Versatile Nanopore Device, Ontera Reduces 'The Lab' to the Size of a Shoebox


We’ve interviewed several CEOs over the years since the Theranos fiasco who avoided any mention or comparison of the blighted company whenever their product came close in appearance. But today’s guest, Murielle Thinard McLane, the CEO of Ontera, jumped at the comparison before Theral could get to it. "Some people might say, well that's the Theranos model. They (Theranos) didn't get it wrong. The demand for a fast, comprehensive point-of-care solution near the patient is there...


share





   n/a
 
 

Mark Chaisson on Two New Structural Variation Papers


If you’re not on the long read sequencing train, you’re not landing in the world of genomics. A new paper out begins, "Structural variants contribute greater diversity at the nucleotide level between two human genomes than another form of genetic variation.”


share





 2019-07-17  n/a
 
 

Mark Chaisson on Two New Structural Variation Papers


If you’re not on the long read sequencing train, you’re not landing in the world of genomics. A new paper out begins, "Structural variants contribute greater diversity at the nucleotide level between two human genomes than another form of genetic variation.”


share





 2019-07-17  n/a
 
 

Early Cancer Detection: Is This Company Ahead of Grail?


The great promise of liquid biopsy technology is in early cancer detection. That is, it's the great future promise. Right? This past month at the annual cancer conference, ASCO, we heard about one such flagship company announcing just which technology they were going to use to do it--DNA methylation.


share





 2019-07-09  n/a
 
 

June 2019 Review with Nathan and Laura: Gene Patents, Grail, Dr. Lynch


Nathan and Laura join Theral for our final review show before the summer break. Have you already headed out on vacation? Take us along and stay current with the top stories in genomics. This month it's gene patents (yes, Congress is really reviving that debate), another gene therapy with another astronomical price tag, and remembering Dr. Henry Lynch of Lynch Syndrome fame.


share





 2019-07-01  n/a
 
 

Should Genomic Screening Be Standard of Care? with Adam Buchanan, Geisinger


Those of us watching every shift in the level of adoption of genomic medicine have our eyes closely glued to Geisinger Health System in Pennsylvania. Adam Buchanan is the Co-Director of Geisinger’s MyCode Genomic Screening and Counseling program, and today we talk to him about the rationale of making genomic screening part of routine medical care.


share





 2019-06-25  n/a
 
 

Should a Genomic Screen Be Standard of Care? with Adam Buchanan, Geisinger


Those of us watching every shift in the level of adoption of genomic medicine have our eyes closely glued to Geisinger Health System in Pennsylvania. Adam Buchanan is the Co-Director of Geisinger’s MyCode Genomic Screening and Counseling program, and today we talk to him about the rationale of making genomic screening part of routine medical care.


share





 2019-06-25  n/a